EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseÜbersichtsarbeit

Melatonin Supplementation in the Management of Irritable Bowel Syndrome: An Updated Systematic Review and Meta‐Analysis

Ghadeer Ahmad Mahdi, Noor Abotaiban iD, Ahmed Farid Gadelmawla iD, Mohammed Alfartaj iD, Saud M Almutairi iD, Faisal E Alenezi iD, Khadigah M Alshammari, Amal A Alsubaiei iD, Abdullah M Alharran iD

Journal of Gastroenterology and Hepatology · 2026-11 · 41 (11) · 3333-3347

DOI: 10.1111/jgh.70743 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 22.09.2026. Verfasst von Ghadeer Ahmad Mahdi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Kuwait Institute for Medical Specializations, Kuwait City, Kuwait. Hauptthemen laut MEDLINE: Melatonin, Irritable Bowel Syndrome, Dietary Supplements. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Irritable bowel syndrome (IBS) is a common disorder of gut–brain interaction characterized by recurrent abdominal pain and altered bowel habits, with substantial effects on quality of life and healthcare utilization. Melatonin has been proposed as a potential adjunctive therapy because of its effects on visceral sensitivity, gastrointestinal motility, and gut–brain signaling. We conducted an updated systematic review and meta‐analysis of randomized placebo‐controlled trials evaluating melatonin supplementation in adults with IBS.

Methods

PubMed, Web of Science, Cochrane CENTRAL, Scopus, and Embase were searched from inception to April 13, 2026. Randomized, double‐blind, placebo‐controlled trials evaluating oral or sublingual melatonin in adults with IBS were included. Parallel‐group trials were quantitatively synthesized, while crossover trials were narratively summarized when outcome reporting was unsuitable for pooling. Risk of bias was assessed using RoB 2.

Results

Seven randomized trials involving 391 participants were included; four contributed to quantitative synthesis and three were narratively reviewed. Melatonin significantly reduced moderate‐to‐severe IBS symptoms versus placebo (RR = 0.52, 95% CI = 0.39–0.71, p < 0.0001), improved pain frequency (SMD = 0.59, 95% CI = 0.27–0.92, p = 0.0003) and improved frequency of defecation (SMD = 0.42, 95% CI = 0.12–0.72, p = 0.0056). No significant differences were observed for overall quality of life or global sleep quality. Abdominal distension and abdominal pain intensity numerically favored melatonin without reaching statistical significance. Reported adverse effects were mild and infrequent.

Conclusion

Melatonin may improve overall IBS symptom severity, pain‐related outcomes, and bowel habit measures, with an acceptable short‐term safety profile. Larger, high‐quality trials are needed to confirm long‐term efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelatoninIrritable Bowel SyndromeDietary SupplementsHumansRandomized Controlled Trials as TopicTreatment OutcomeQuality of LifeAdultAbdominal PainDefecationGastrointestinal Motility

Stichwörter der Autor:innen

IBSirritable bowel syndromemelatoninmeta‐analysissystematic review

Substanzen

Melatonin

Autor:innen und Institutionen

  • Kuwait Institute for Medical Specializations, Kuwait City, Kuwait.
  • Kuwaiti Board of Internal Medicine, Kuwait Institute for Medical Specializations, Kuwait City, Kuwait.
  • Faculty of Medicine, Menoufia University, Menoufia, Egypt.
  • Royal College of Surgeons, Dublin, Ireland.
  • Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.
  • Queen's University, Kingston, Ontario, Canada.

ORCID-Profile: Noor Abotaiban, Ahmed Farid Gadelmawla, Mohammed Alfartaj, Saud M Almutairi, Faisal E Alenezi, Amal A Alsubaiei, Abdullah M Alharran

Zitieren

APA

Mahdi, G. A., Abotaiban, N., Gadelmawla, A. F., Alfartaj, M., Almutairi, S. M., Alenezi, F. E., Alshammari, K. M., Alsubaiei, A. A., & Alharran, A. M. (2026). Melatonin Supplementation in the Management of Irritable Bowel Syndrome: An Updated Systematic Review and Meta‐Analysis. Journal of Gastroenterology and Hepatology, 41(11), 3333-3347. https://doi.org/10.1111/jgh.70743

Vancouver

Mahdi GA, Abotaiban N, Gadelmawla AF, Alfartaj M, Almutairi SM, Alenezi FE, et al. Melatonin Supplementation in the Management of Irritable Bowel Syndrome: An Updated Systematic Review and Meta‐Analysis. Journal of Gastroenterology and Hepatology. 2026;41(11):3333-3347. doi:10.1111/jgh.70743

BibTeX
@article{Mahdi2026,
  author = {Mahdi, Ghadeer Ahmad and Abotaiban, Noor and Gadelmawla, Ahmed Farid and Alfartaj, Mohammed and Almutairi, Saud M and Alenezi, Faisal E and Alshammari, Khadigah M and Alsubaiei, Amal A and Alharran, Abdullah M},
  title = {Melatonin Supplementation in the Management of Irritable Bowel Syndrome: An Updated Systematic Review and Meta‐Analysis},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  volume = {41},
  number = {11},
  pages = {3333--3347},
  doi = {10.1111/jgh.70743}
}
Kostenlos starten →